CN104288111A - Ginsenoside Rg3 poly(lactic-co-glycolic acid) nano microsphere and preparation method thereof - Google Patents
Ginsenoside Rg3 poly(lactic-co-glycolic acid) nano microsphere and preparation method thereof Download PDFInfo
- Publication number
- CN104288111A CN104288111A CN201410490644.3A CN201410490644A CN104288111A CN 104288111 A CN104288111 A CN 104288111A CN 201410490644 A CN201410490644 A CN 201410490644A CN 104288111 A CN104288111 A CN 104288111A
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- glycolic acid
- polylactic
- nano microsphere
- acid nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a ginsenoside Rg3 poly(lactic-co-glycolic acid) (PLGA) nano microsphere and a preparation method thereof. The preparation method of the ginsenoside Rg3 poly(lactic-co-glycolic acid) nano microsphere comprises the following steps: S1, dissolving ginsenoside Rg3 in dimethyl sulfoxide to obtain a first liquid with a first predetermined concentration, and dissolving poly(lactic-co-glycolic acid) copolymer into dichloromethane to obtain a second liquid with a second predetermined concentration; S2, adding the first liquid in a predetermined proportion into the second liquid to perform ultrasonic treatment to form a turbid liquid; S3, adding the turbid liquid into an aqueous liquid containing polyvinyl alcohol to perform ultrasonic emulsion to obtain emulsion; and S4, drying the emulsion, centrifugally separating and washing, and freeze-drying the emulsion after curing the microspheres of the microsphere of the emulsion to obtain the ginsenoside Rg3 poly(lactic-co-glycolic acid) nano microsphere. According to the preparation method of the ginsenoside Rg3 poly(lactic-co-glycolic acid) nano microsphere of the embodiment of the invention, the prepared ginsenoside PLGA microsphere is good in pesticide effect.
Description
Technical field
The present invention relates to medical art, more specifically, relate to a kind of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere and preparation method thereof.
Background technology
Ginsenoside Rg3 is a kind of tetracyclic triterpenes saponin compound be present in Radix Ginseng, molecular weight is 784.13, there are 20 (R)-ginsenoside Rg3s and 20 (s)-ginsenoside Rg3, two kinds of enantiomeric form, wherein 20 (R)-ginsenoside Rg3 stable chemical natures, structural formula is as follows:
Ginsenoside Rg3 has many-sided pharmacological action, can significantly improve the immunologic function of tumor-bearing mice; In Tumor suppression, new vessels is formed; Stop the implantation of cancerous cell in blood vessel wall that come off; Inhibition tumor cell, to the infiltration of blood vessel wall basement membrane, has remarkable anti-infiltration, metastasis effect.Clinical experiment confirms that Rg3 can effectively suppress pulmonary carcinoma, hepatocarcinoma, gastric cancer, intestinal cancer, growth of breast cancers, obviously improves clinical symptoms, raising life quality, prevention and therapy cancer, cardiovascular function of improving, anti-platelet aggregation, protection cranial nerve cell, improves immunity of organisms.
But, 20 (R)-ginsenoside Rg3s are not soluble in water, by finding the pharmacokinetic of ginsenoside Rg3, absorb fast after Rg3 is oral, metabolism is fast, and blood drug level is low, and its utilization ratio of drug is reduced, significantly limit the performance of its clinical drug effect, also limit the application of its parenteral administration route simultaneously.
Summary of the invention
The present invention is intended to one of solve the problems of the technologies described above at least to a certain extent.For this reason, one object of the present invention is the preparation method proposing a kind of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere, the ginsenoside Rg3 polylactic-co-glycolic acid Nano microsphere obtained by this preparation method can pass through parenteral administration, improve blood drug level, play drug effect better.
Another object of the present invention is to propose a kind of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere be prepared from by above-mentioned preparation method.
The preparation method of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere of embodiment according to a first aspect of the present invention, comprise the following steps: S1: ginsenoside Rg3 is dissolved in dimethyl sulfoxide, obtain the first solution of the first predetermined concentration, Poly(D,L-lactide-co-glycolide is dissolved in dichloromethane, obtains the second solution of the second predetermined concentration; S2: described first solution of predetermined ratio is joined in described second solution, ultrasonic, form suspension; S3: joined by described suspension in the aqueous solution containing polyvinyl alcohol, ultrasonic emulsification, obtains emulsion; S4: by described emulsion dried, until described emulsion microsphere solidification after, centrifugalize and wash, lyophilizing, obtain ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere.
According to the preparation method of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere of the embodiment of the present invention, the ginsenoside PLGA microsphere prepared solves ginsenoside's poorly water-soluble, not easily absorbed shortcoming after oral, can by parenteral administration such as injections after being prepared into microsphere, along with the degraded of microsphere, progressively discharge the medicine wherein wrapping and carry, interiorly for a long time can maintain more stable blood drug level, therapeutic effect is better, simultaneously, the ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere prepared can reduce times for spraying, reduces side effect.
In addition, the preparation method of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere according to the above embodiment of the present invention, can also have following additional technical characteristic:
According to one embodiment of present invention, described first concentration is 40-80mg/ml, and described second concentration is 20-40mg/ml.
According to one embodiment of present invention, the volume ratio of described second solution and described first solution is 10-50.
According to one embodiment of present invention, in the aqueous solution of described polyvinyl alcohol, the volume fraction of polyvinyl alcohol is 1-2%.
According to one embodiment of present invention, the volume ratio of the aqueous solution of described suspension and described polyvinyl alcohol is 1:10-15.
According to one embodiment of present invention, described step S4 comprises: S41: described emulsion joined in the aqueous solution of described polyvinyl alcohol, volatilized by magnetic agitation; S42: after the microsphere solidification of described emulsion, by High speed refrigerated centrifuge centrifugalize, after deionized water wash, lyophilizing is preserved, and obtains described ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere.
According to one embodiment of present invention, the volume ratio of the aqueous solution of described emulsion and described polyvinyl alcohol is 1:3-5.
According to one embodiment of present invention, the speed of magnetic agitation is 1000r, and the time of magnetic agitation is 3-4 hour.
Ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere of embodiment according to a second aspect of the present invention, described ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere adopts and is prepared from according to the preparation method of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere of above-described embodiment.
Additional aspect of the present invention and advantage will part provide in the following description, and part will become obvious from the following description, or be recognized by practice of the present invention.
Accompanying drawing explanation
Above-mentioned and/or additional aspect of the present invention and advantage will become obvious and easy understand from accompanying drawing below combining to the description of embodiment, wherein:
Fig. 1 is the flow chart of the preparation method of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere according to the embodiment of the present invention;
Fig. 2 is the microsphere scanning electron microscope (SEM) photograph of the ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere according to different embodiments of the invention;
Fig. 3 is the microspherulite diameter scatter chart of the ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere according to the embodiment of the present invention;
Fig. 4 is according to the outer controlled release curve chart of the microsphere of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere of the embodiment of the present invention;
Fig. 5 a to Fig. 5 c is the cell survival rate comparison diagram according to different time sections after ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere of the embodiment of the present invention and Rg3 drug effect HepG2 cell;
Fig. 6 a is the cell survival rate figure after variable concentrations ginsenoside Rg3 polylactic-co-glycolic acid Nano microsphere acts on HepG2 cell;
Fig. 6 b is the cell survival rate figure after variable concentrations Rg3 acts on HepG2 cell.
Detailed description of the invention
Be described below in detail embodiments of the invention, the example of described embodiment is shown in the drawings, and wherein same or similar label represents same or similar element or has element that is identical or similar functions from start to finish.Be exemplary below by the embodiment be described with reference to the drawings, be intended to for explaining the present invention, and can not limitation of the present invention be interpreted as.
First the preparation method of the ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere according to the embodiment of the present invention is specifically described by reference to the accompanying drawings below.
As shown in Figure 1, comprise the following steps according to the preparation method of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere of the embodiment of the present invention:
S1: ginsenoside Rg3 is dissolved in dimethyl sulfoxide (DMSO), obtain the first solution of the first predetermined concentration, Poly(D,L-lactide-co-glycolide is dissolved in dichloromethane (DCM), obtains the second solution of the second predetermined concentration.
S2: described first solution of predetermined ratio is joined in described second solution, ultrasonic, form suspension.
S3: joined by described suspension in the aqueous solution containing polyvinyl alcohol (PVA), ultrasonic emulsification, obtains emulsion.
S4: by described emulsion dried, until described emulsion microsphere solidification after, centrifugalize and wash, lyophilizing, obtain ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere.
According to the preparation method of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere of the embodiment of the present invention, the ginsenoside PLGA microsphere prepared solves ginsenoside's poorly water-soluble, not easily absorbed shortcoming after oral, can by parenteral administration such as injections after being prepared into microsphere, along with the degraded of microsphere, progressively discharge the medicine wherein wrapping and carry, interiorly for a long time can maintain more stable blood drug level, therapeutic effect is better, simultaneously, the ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere prepared can reduce times for spraying, reduces side effect.
Wherein it should be noted that, Poly(D,L-lactide-co-glycolide (poly (lactic-co-glycolic acid), PLGA) be a kind of degradable functional polymer organic compound, be polymerized at random by two kinds of monomer molecule-lactic acid (LA) and hydroxyacetic acid (GA) and formed, there is good stability, be easy to by phagocyte picked-up, the advantages such as specific tissue and organ can be navigated to by adsorbing corresponding part at particle surface.The good biocompatibility and safety that PLGA has has been assert by U.S. food Drug Administration (FDA), is widely used in the prehuman all kinds of clinic study of order.Two kinds of product lactic acid after PLGA hydrolysis and hydroxyacetic acid are the by-products of body metabolism approach, nontoxic to human-body safety, therefore PLGA biological safety is high, along with body metabolism, can not there is cumulative appearance in its repetitively administered, be a kind of good drug delivery vehicle later in vivo.
According to one embodiment of present invention, described first concentration is 40-80mg/ml, and described second concentration is 20-40mg/ml.Further, the volume ratio of described second solution and described first solution is 10-50.That is, ginsenoside Rg3 obtains the first solution that ginsenoside Rg3's concentration is 40-80mg/ml after being dissolved in dimethyl sulfoxide, Poly(D,L-lactide-co-glycolide obtains the second solution that Poly(D,L-lactide-co-glycolide concentration is 20-40mg/ml after being dissolved in dichloromethane, and the volume ratio of the first solution and the second solution is 1:10-50.
Alternatively, in detailed description of the invention more of the present invention, in the aqueous solution of described polyvinyl alcohol, the volume fraction of polyvinyl alcohol can be 1-2%.Further, the volume ratio of the aqueous solution of described suspension and described polyvinyl alcohol is 1:10-15.
Preferably, according to one embodiment of present invention, described step S4 comprises: S41: described emulsion joined in the aqueous solution of described polyvinyl alcohol, volatilized by magnetic agitation; S42: after the microsphere solidification of described emulsion, by High speed refrigerated centrifuge centrifugalize, after deionized water wash, lyophilizing is preserved, and obtains described ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere.Wherein, the volume ratio of the aqueous solution of described emulsion and described polyvinyl alcohol can be 1:3-5, and the speed of magnetic agitation can be 1000r, and the time of magnetic agitation can be 3-4 hour.
In other words, preparation method according to ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere of the embodiment of the present invention can be: first take PLGA and be dissolved in dichloromethane (DCM) solution, obtained PLGA solution concentration is 20 ~ 30mg/ml, ginsenoside Rg3 is dissolved in dimethyl sulfoxide (DMSO), obtained drug solution concentration is 40 ~ 80mg/ml, then join in appropriate PLGA solution according to the drug solution of the accurate measured amounts of the ratio of 1:10 ~ 20, rapid ultrasonic emulsification, obtain PLGA drug suspension, this suspension is joined 10 ~ 15 times containing in 1 ~ 2% polyvinyl alcohol (PVA) solution, ultrasonic emulsification, the emulsion obtained joins 3 ~ 5 times containing in the solution of 1 ~ 2%PVA, magnetic agitation 1000r 3 ~ 4 hours, organic solvent volatilizes, after microsphere has solidified, centrifugalize obtains microsphere, with deionized water wash 3 ~ 5 times, lyophilization, obtain microsphere.
Generally speaking, according to ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere that the preparation method of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere of the embodiment of the present invention is prepared from, solve ginsenoside's poorly water-soluble, not easily absorbed shortcoming after oral, can by parenteral administration such as injections after being prepared into microsphere, along with the degraded of microsphere, progressively discharge the medicine wherein wrapping and carry, interiorly for a long time can maintain more stable blood drug level, therapeutic effect is better, simultaneously, the ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere prepared can reduce times for spraying, reduce side effect.
It should be noted that in addition, according to ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere of the embodiment of the present invention, described ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere can adopt and be prepared from according to the preparation method of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere of above-described embodiment, and additive method also can be adopted to be prepared from.
Below in conjunction with specific embodiment description according to ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere of the embodiment of the present invention and preparation method thereof.
Embodiment 1: be first dissolved in DMSO by ginsenoside Rg3, drug level is 40mg/ml, is dissolved in by PLGA in DCM, and concentration is 30mg/ml.Precision measures 1ml PLGA solution, adds ginsenoside Rg3's solution 80 μ l wherein, under ultrasonic power 210w, surpasses 5 seconds, stop 5 seconds, ultrasonic 1 minute.
This suspension is joined rapidly 10ml to be contained in the aqueous solution of 1%PVA, repeat aforementioned ultrasonic condition, the emulsion of gained is poured into 30ml and contains in the aqueous solution of 1%PVA, 1000r magnetic agitation is after 3 hours, the freezing centrifugalize microsphere of high speed, deionized water wash 3 times, is stored in-20 DEG C after lyophilizing.Microsphere stereoscan photograph as shown in Figure 2 A.
Embodiment 2: be first dissolved in DMSO by ginsenoside Rg3, drug level is 40mg/ml, is dissolved in by PLGA in DCM, and concentration is 30mg/ml.Precision measures 1ml PLGA solution, adds ginsenoside Rg3's solution 60 μ l wherein, under ultrasonic power 210w, surpasses 5 seconds, stop 5 seconds, ultrasonic 1 minute.
This suspension is joined rapidly 10ml to be contained in the aqueous solution of 1%PVA, repeat aforementioned ultrasonic condition, the emulsion of gained is poured into 30ml and contains in the aqueous solution of 1%PVA, 1000r magnetic agitation is after 3 hours, the freezing centrifugalize microsphere of high speed, deionized water wash 3 times, is stored in-20 DEG C after lyophilizing.Microsphere stereoscan photograph as shown in Figure 2 B.
Embodiment 3: be first dissolved in DMSO by ginsenoside Rg3, drug level is 40mg/ml, is dissolved in by PLGA in DCM, and concentration is 30mg/ml.Precision measures 1ml PLGA solution, adds ginsenoside Rg3's solution 40 μ l wherein, under ultrasonic power 210w, surpasses 5 seconds, stop 5 seconds, ultrasonic 1 minute.
This suspension is joined rapidly 10ml to be contained in the aqueous solution of 1%PVA, repeat aforementioned ultrasonic condition, the emulsion of gained is poured into 30ml and contains in the aqueous solution of 1%PVA, 1000r magnetic agitation is after 3 hours, the freezing centrifugalize microsphere of high speed, deionized water wash 3 times, is stored in-20 DEG C after lyophilizing.Microsphere stereoscan photograph as shown in Figure 2 C.
Embodiment 4: be first dissolved in DMSO by ginsenoside Rg3, drug level is 40mg/ml, is dissolved in by PLGA in DCM, and concentration is 30mg/ml.Precision measures 3ml PLGA solution, adds ginsenoside Rg3's solution 180 μ l wherein, under ultrasonic power 230w, surpasses 5 seconds, stop 5 seconds, ultrasonic 1 minute.
This suspension is joined rapidly 30ml to be contained in the aqueous solution of 1%PVA, under ultrasonic power 340w, surpass 5 seconds, stop 5 seconds, ultrasonic 1 minute, the emulsion of gained is poured into 90ml and contains in the aqueous solution of 1%PVA, 1000r magnetic agitation is after 3 hours, the freezing centrifugalize microsphere of high speed, deionized water wash 3 times, is stored in-20 DEG C after lyophilizing.Microsphere stereoscan photograph as shown in Figure 2 D.
After adopting above condition to prepare microsphere, scanning electron microscopic observation microsphere surface form, as shown in accompanying drawing 2A to 2D, when PLGA liquor capacity is certain, ginsenoside Rg3's liquor capacity reduces, balling-up better effects if, thus obtained microsphere surface is more smooth, does not have medicine to separate out.The microsphere (Fig. 2 D) prepared under embodiment 4 condition, smooth surface, size is at nanoscale.
Fig. 3 is the ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere particle size distribution diagram line according to the embodiment of the present invention.After measured, ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere envelop rate is 68.2%, and drug loading is 9.6%, and as shown in Figure 4, within 40 days, release in vitro reaches 70% to external controlled-release profile.
In addition, after extended volume, not only once can prepare a large amount of ginsenoside Rg3's polylactic-co-glycolic acid Nano microspheres, for follow-up study, and illustrate that this microspheres can amplify, be beneficial to suitability for industrialized production.
Embodiment 5: ginsenoside Rg3's microsphere suppresses the propagation (mtt assay) of human liver cancer cell HepG2
This experiment using the normal growth cell without drug treating as negative control, with the auxocyte of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere process for positive control.
Choose 0.5 μ g/mL, 10 μ g/mL, 50 μ g/mL, 100 μ g/mL, 200 μ g/mL, five ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere Concentraton gradient, measure the cell survival rate after 24h, 48h, 72h.Specific experiment step is as follows:
(1) in 96 orifice plates, every hole adds the cell suspension of 100 μ L containing the difference detection cell of 1 × 104 cells/well.Culture plate is put into containing 5%CO2, preculture 24h in the cell culture incubator of 37 DEG C;
(2) according to microsphere encapsulation rate, the DMEM culture medium of the PLGA/Rg3 Nano microsphere serum-free of the different preparation conditions after lyophilizing is diluted to Rg3 concentration and is respectively 0.5 μ g/mL, 10 μ g/mL, 50 μ g/mL, 100 μ g/mL, 200 μ g/mL, five Concentraton gradient as experimental group; The Rg3/DMSO solution of configuration correspondence is as positive controls;
(3) in 96 orifice plates, every hole adds the mixed liquor of 100 μ L variable concentrations gradients, arranges blank control wells and zeroing hole;
(4) 96 orifice plates are placed on containing 5%CO2, cultivate in the cell culture incubator of 37 DEG C, cell is taken out respectively at 24h, 48h, 72h, 10 μ L MTT solution are added in the 96 each holes of orifice plate, after putting into incubator continuation cultivation 4h, add 150 μ L DMSO more dissolving crystallized, then measure the light absorption value at 492nm place.
Experimental result is as shown in Fig. 5 a to 5c, and wherein, Fig. 5 a represents the cell survival rate after 24 hours, and Fig. 5 b represents the cell survival rate after 48 hours, and Fig. 5 c represents the cell survival rate after 72 hours.
Particularly, at one time in scope, along with the increase of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere drug concentration gradient, there is downward trend in HepG2 cell survival rate.During 24h, the cell survival rate under the effect of least concentration PLGA/Rg3 microsphere is 95.4%, and when maximum concentration, survival rate drops to 70.6%.Cell survival rate under least concentration Rg3 drug effect is 98.1%, and when maximum concentration, survival rate drops to 78.3%.Also there is identical situation of change in 48h and 72h.
Under the condition of same drug level at one time, along with ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere (Fig. 6 a) and the Rg3 prolongation of (Fig. 6 b) medicine to the HepG2 cytosis time and the increase of concentration, the survival rate of cell presents downward trend, has time and dose dependent.Cell survival rate after the effect of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere is lower than the cell survival rate after Rg3 medicine direct effect.During 72h, cell survival rate under ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere effect of 200ug/mL concentration is 53.7% (Fig. 6 a), and the cell survival rate under comparable sodium after Rg3 effect is 61.3% (Fig. 6 b), therefore, the antitumor activity of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere ball is better than Rg3.
In the description of this description, specific features, structure, material or feature that the description of reference term " embodiment ", " some embodiments ", " example ", " concrete example " or " some examples " etc. means to describe in conjunction with this embodiment or example are contained at least one embodiment of the present invention or example.In this manual, identical embodiment or example are not necessarily referred to the schematic representation of above-mentioned term.And the specific features of description, structure, material or feature can combine in an appropriate manner in any one or more embodiment or example.
Although illustrate and describe embodiments of the invention above, be understandable that, above-described embodiment is exemplary, can not be interpreted as limitation of the present invention, those of ordinary skill in the art can change above-described embodiment within the scope of the invention when not departing from principle of the present invention and aim, revising, replacing and modification.
Claims (9)
1. a preparation method for ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere, is characterized in that, comprises the following steps:
S1: ginsenoside Rg3 be dissolved in dimethyl sulfoxide, obtains the first solution of the first predetermined concentration, is dissolved in by Poly(D,L-lactide-co-glycolide in dichloromethane, obtains the second solution of the second predetermined concentration;
S2: described first solution of predetermined ratio is joined in described second solution, ultrasonic, form suspension;
S3: joined by described suspension in the aqueous solution containing polyvinyl alcohol, ultrasonic emulsification, obtains emulsion;
S4: by described emulsion dried, until described emulsion microsphere solidification after, centrifugalize and wash, lyophilizing, obtain ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere.
2. the preparation method of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere according to claim 1, is characterized in that, described first concentration is 40-80mg/ml, and described second concentration is 20-40mg/ml.
3. the preparation method of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere according to claim 1, is characterized in that, the volume ratio of described second solution and described first solution is 10-50.
4. the preparation method of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere according to claim 1, is characterized in that, in the aqueous solution of described polyvinyl alcohol, the volume fraction of polyvinyl alcohol is 1-2%.
5. the preparation method of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere according to claim 1, is characterized in that, the volume ratio of the aqueous solution of described suspension and described polyvinyl alcohol is 1:10-15.
6. the preparation method of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere according to claim 1, it is characterized in that, described step S4 comprises:
S41: described emulsion is joined in the aqueous solution of described polyvinyl alcohol, volatilized by magnetic agitation;
S42: after the microsphere solidification of described emulsion, by High speed refrigerated centrifuge centrifugalize, after deionized water wash, lyophilizing is preserved, and obtains described ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere.
7. the preparation method of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere according to claim 6, is characterized in that, the volume ratio of the aqueous solution of described emulsion and described polyvinyl alcohol is 1:3-5.
8. the preparation method of ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere according to claim 6, is characterized in that, the speed of magnetic agitation is 1000r, and the time of magnetic agitation is 3-4 hour.
9. ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere, it is characterized in that, described ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere adopts the preparation method of the ginsenoside Rg3's polylactic-co-glycolic acid Nano microsphere according to any one of claim 1-8 to be prepared from.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410490644.3A CN104288111A (en) | 2014-09-23 | 2014-09-23 | Ginsenoside Rg3 poly(lactic-co-glycolic acid) nano microsphere and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410490644.3A CN104288111A (en) | 2014-09-23 | 2014-09-23 | Ginsenoside Rg3 poly(lactic-co-glycolic acid) nano microsphere and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104288111A true CN104288111A (en) | 2015-01-21 |
Family
ID=52308229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410490644.3A Pending CN104288111A (en) | 2014-09-23 | 2014-09-23 | Ginsenoside Rg3 poly(lactic-co-glycolic acid) nano microsphere and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104288111A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105708847A (en) * | 2016-02-02 | 2016-06-29 | 成都大学 | Preparing method and application of ginsenoside-multi-component jointly-loading targeting nanometer system |
| CN106361724A (en) * | 2015-07-24 | 2017-02-01 | 富力 | 20(R)-ginsenoside Rg3 slow release nanometer microsphere composition, and preparation method thereof |
| CN107519189A (en) * | 2016-06-22 | 2017-12-29 | 智能合成生物中心 | Include Immune-enhancing effect composition GF1 as active ingredient |
| CN111265549A (en) * | 2020-03-02 | 2020-06-12 | 苏州大学 | Surface PD-L1 molecule over-expressed mesenchymal stem cell membrane coated bionic nanoparticle and preparation and application thereof |
| CN113750229A (en) * | 2021-10-18 | 2021-12-07 | 浙江省农业科学院 | Nano granules of saponin of ginseng stem and leaf, preparation method and application |
| CN114159615A (en) * | 2021-12-16 | 2022-03-11 | 福州大学 | Hydrogel wound dressing for indicating wound pH and ultrasound-responsive drug delivery |
| CN115644175A (en) * | 2022-11-14 | 2023-01-31 | 中国农业科学院农产品加工研究所 | Preparation method of nano embedded pesticide and nano embedded pesticide |
-
2014
- 2014-09-23 CN CN201410490644.3A patent/CN104288111A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| 金玺圆: "PLGA微球的制备及其作为肿瘤药物递送载体的研究", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106361724A (en) * | 2015-07-24 | 2017-02-01 | 富力 | 20(R)-ginsenoside Rg3 slow release nanometer microsphere composition, and preparation method thereof |
| CN105708847A (en) * | 2016-02-02 | 2016-06-29 | 成都大学 | Preparing method and application of ginsenoside-multi-component jointly-loading targeting nanometer system |
| CN105708847B (en) * | 2016-02-02 | 2019-01-04 | 成都大学 | Ginsenoside multicomponent carries the preparation method and applications of targeted nano system altogether |
| CN107519189A (en) * | 2016-06-22 | 2017-12-29 | 智能合成生物中心 | Include Immune-enhancing effect composition GF1 as active ingredient |
| US10682366B2 (en) | 2016-06-22 | 2020-06-16 | Intelligent Synthetic Biology Center | Method for enhancing immunity using ginsenoside F1 as an active ingredient |
| CN111265549A (en) * | 2020-03-02 | 2020-06-12 | 苏州大学 | Surface PD-L1 molecule over-expressed mesenchymal stem cell membrane coated bionic nanoparticle and preparation and application thereof |
| CN113750229A (en) * | 2021-10-18 | 2021-12-07 | 浙江省农业科学院 | Nano granules of saponin of ginseng stem and leaf, preparation method and application |
| CN114159615A (en) * | 2021-12-16 | 2022-03-11 | 福州大学 | Hydrogel wound dressing for indicating wound pH and ultrasound-responsive drug delivery |
| CN115644175A (en) * | 2022-11-14 | 2023-01-31 | 中国农业科学院农产品加工研究所 | Preparation method of nano embedded pesticide and nano embedded pesticide |
| CN115644175B (en) * | 2022-11-14 | 2023-11-10 | 中国农业科学院农产品加工研究所 | Preparation method of nano-embedded pesticide and nano-embedded pesticide |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104288111A (en) | Ginsenoside Rg3 poly(lactic-co-glycolic acid) nano microsphere and preparation method thereof | |
| He et al. | Localized multidrug co-delivery by injectable self-crosslinking hydrogel for synergistic combinational chemotherapy | |
| Men et al. | Delivering instilled hydrophobic drug to the bladder by a cationic nanoparticle and thermo-sensitive hydrogel composite system | |
| CN104434806B (en) | Lipid-mixed poly (lactic-co-glycolic acid) (PLGA) nanoparticle having high drug loading amount and active targeting effect | |
| CN103705469B (en) | A kind of honokiol nanoparticle and preparation method thereof | |
| CN102871966B (en) | Nano drug carrier particles for improving bioavailability of rapamycin and preparation method thereof | |
| CN104055751A (en) | Long-circulating and targeting synergistic multifunctional anti-tumor targeting nano-drug carrier | |
| CN103877029B (en) | A kind of magnetic carries the preparation method of 5-fluorouracil PLGA material | |
| CN102125547A (en) | Pharmaceutical composition containing gambogic acid medicament and preparation method thereof | |
| CN101804021A (en) | Preparation method of polyene-containing taxol nanoparticle mixed micelle preparation and freeze-drying agent | |
| Yi et al. | Synthesis, characterization, and formulation of poly-puerarin as a biodegradable and biosafe drug delivery platform for anti-cancer therapy | |
| CN104324384A (en) | Hyaluronic acid-quercetin conjugate self-assembly micelle preparation and preparation method thereof | |
| CN105012271A (en) | Doxorubicin and TRAIL co-supported albumin nanoparticle targeting preparation and preparation method thereof | |
| CN104337851A (en) | Preparation method of oleum fructus bruceae nano structure lipid carrier and freeze-dried powder thereof | |
| Yang et al. | A novel self-targeting theranostic nanoplatform for photoacoustic imaging-monitored and enhanced chemo-sonodynamic therapy | |
| Ma et al. | Multi-functionalized dendrimers for targeted co-delivery of sorafenib and paclitaxel in liver cancers | |
| CN108912349A (en) | Polylactic acid microsphere and preparation method thereof and the application in medicament slow release | |
| Hou et al. | Preparation and in vitro evaluation of an ultrasound-triggered drug delivery system: 10-Hydroxycamptothecin loaded PLA microbubbles | |
| CN106361724B (en) | A sustained release nanometer microsphere composition of 20(R) -ginsenoside Rg3 and its preparation method | |
| CN109200021B (en) | Lysosome targeted pH sensitive nanoparticle and preparation method and application thereof | |
| US20120029064A1 (en) | formulation of silibinin with high efficacy and prolonged action and the preparation method thereof | |
| CN107096039B (en) | A kind of double medicines that carry of magnetic targeted pass release system and preparation method thereof | |
| CN103655484A (en) | Method for preparing paclitaxel sustained-release microspheres by use of self-assembly technology and product thereof | |
| CN104434792A (en) | Polymer micelle, preparation method thereof, antitumor pharmaceutical composition, preparation and preparation method thereof | |
| CN102836147B (en) | Paclitaxel-entrapped biodegradable nanocomposite and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150121 |
|
| RJ01 | Rejection of invention patent application after publication |